Cubist Pharmaceuticals, Inc. Announces Full-Year 2012 Revenues and Provides Business Update

Published: Jan 07, 2013

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced unaudited fourth quarter and full-year 2012 revenues and provided business updates, including the expected timing of data readouts for two ongoing Phase 3 clinical trials of CXA-201 (ceftolozane/tazobactam).

Back to news